Given Imaging’s PillCam Colon 2 Strategy Shift Will Delay Screening Claim
This article was originally published in The Gray Sheet
Firm initially will pursue diagnostic imaging claim for its PillCam Colon 2 video capsule, rather than a screening claim, as the fastest route to U.S. market. The strategy shift follows preliminary clinical trial data review.
You may also be interested in...
Given Imaging, soon to be part of Covidien, gained clearance for PillCam Colon capsule endoscopy device. FDA approves its first continuous glucose monitoring system for kids. Congress makes progress in the sustainable growth rate formula bill. More news.
The $860 million purchase agreement will give Covidien the dominant capsule endoscopy platform on the market as the company hopes for FDA approval this year of PillCam COLON 2 as a less invasive alternative for patients who are unable to undergo a colonoscopy.
Japan will reimburse PillCam COLON. 3-D mammography CPT code application withdrawn from AMA CPT Editorial Panel meeting. CMS unveils new virtual research data-sharing tool.